Dawn C. Bir served as Interim President and Chief Executive Officer of Geron Corporation, a clinical-stage biopharmaceutical company focused on advancing therapies for hematologic malignancies, from November 2023 until September 2024. In this pivotal role, she led the company through a transformative period, overseeing the successful U.S. FDA approval of Rytelo™ (imetelstat), Geron's first commercial product for the treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. Her leadership ensured seamless execution of regulatory milestones, commercialization strategies, and corporate governance during a critical phase of the company's evolution. Prior to her interim CEO position, Bir held the role of Executive Vice President, General Counsel, and Corporate Secretary at Geron since joining in 2019. She brought extensive expertise in biotechnology law, having previously served as Senior Vice President, General Counsel, and Corporate Secretary at Relypsa, Inc., where she managed legal operations until its acquisition by Galapagos NV. Earlier in her career, Bir was Vice President, Associate General Counsel at Onyx Pharmaceuticals, contributing to legal strategies during its growth and eventual acquisition by Amgen. She holds a J.D. from Santa Clara University School of Law and a B.A. from the University of California, Davis. Bir's achievements include navigating complex regulatory landscapes, structuring strategic partnerships, and fostering compliance in high-stakes biotech environments. Her tenure at Geron not only facilitated the landmark FDA approval of Rytelo but also positioned the company for sustained growth in the competitive myelofibrosis therapeutic space, earning her recognition as a key architect of the firm's commercial breakthrough.